NO327285B1 - Farmasoytisk sammensetning med langvarig frigivelse og anvendelse derav - Google Patents
Farmasoytisk sammensetning med langvarig frigivelse og anvendelse derav Download PDFInfo
- Publication number
- NO327285B1 NO327285B1 NO20011695A NO20011695A NO327285B1 NO 327285 B1 NO327285 B1 NO 327285B1 NO 20011695 A NO20011695 A NO 20011695A NO 20011695 A NO20011695 A NO 20011695A NO 327285 B1 NO327285 B1 NO 327285B1
- Authority
- NO
- Norway
- Prior art keywords
- weight
- pharmaceutical composition
- average molecular
- number average
- molecular weight
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 30
- 230000002035 prolonged effect Effects 0.000 title description 7
- 239000000203 mixture Substances 0.000 claims description 54
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 36
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 36
- 229920001477 hydrophilic polymer Polymers 0.000 claims description 21
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 18
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 18
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 claims description 16
- -1 poly(ethylene oxide) Polymers 0.000 claims description 14
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 13
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 13
- 229960003765 fluvastatin Drugs 0.000 claims description 11
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 10
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 10
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 8
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 8
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000013543 active substance Substances 0.000 description 34
- 238000004090 dissolution Methods 0.000 description 19
- 239000002552 dosage form Substances 0.000 description 17
- 230000000052 comparative effect Effects 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 238000003756 stirring Methods 0.000 description 11
- 239000011159 matrix material Substances 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 230000002028 premature Effects 0.000 description 9
- 230000037406 food intake Effects 0.000 description 7
- 239000008363 phosphate buffer Substances 0.000 description 7
- 239000000499 gel Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 229960000868 fluvastatin sodium Drugs 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000013268 sustained release Methods 0.000 description 5
- 239000012730 sustained-release form Substances 0.000 description 5
- 229920003091 Methocel™ Polymers 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 235000015497 potassium bicarbonate Nutrition 0.000 description 4
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 4
- 239000011736 potassium bicarbonate Substances 0.000 description 4
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000008351 acetate buffer Substances 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 239000012738 dissolution medium Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000004880 explosion Methods 0.000 description 2
- 238000001879 gelation Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- BBMHARZCALWXSL-UHFFFAOYSA-M sodium dihydrogenphosphate monohydrate Chemical compound O.[Na+].OP(O)([O-])=O BBMHARZCALWXSL-UHFFFAOYSA-M 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 102220487426 Actin-related protein 2/3 complex subunit 3_K15M_mutation Human genes 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229940082483 carnauba wax Drugs 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229960005168 croscarmellose Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229940094025 potassium bicarbonate Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17249198A | 1998-10-14 | 1998-10-14 | |
| PCT/EP1999/007627 WO2000021525A2 (en) | 1998-10-14 | 1999-10-12 | Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20011695D0 NO20011695D0 (no) | 2001-04-04 |
| NO20011695L NO20011695L (no) | 2001-05-30 |
| NO327285B1 true NO327285B1 (no) | 2009-06-02 |
Family
ID=22627919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20011695A NO327285B1 (no) | 1998-10-14 | 2001-04-04 | Farmasoytisk sammensetning med langvarig frigivelse og anvendelse derav |
Country Status (30)
| Country | Link |
|---|---|
| EP (1) | EP1121116B1 (pl) |
| JP (2) | JP2002527388A (pl) |
| KR (1) | KR100517090B1 (pl) |
| CN (1) | CN1196481C (pl) |
| AR (2) | AR020780A1 (pl) |
| AT (1) | ATE382345T1 (pl) |
| AU (1) | AU765475B2 (pl) |
| BR (1) | BR9911648A (pl) |
| CA (1) | CA2346868C (pl) |
| CO (1) | CO5140079A1 (pl) |
| CY (1) | CY1107874T1 (pl) |
| DE (1) | DE69937891T2 (pl) |
| DK (1) | DK1121116T3 (pl) |
| ES (1) | ES2297936T3 (pl) |
| HK (1) | HK1040920B (pl) |
| HU (1) | HUP0104268A3 (pl) |
| ID (1) | ID29350A (pl) |
| IL (2) | IL142375A0 (pl) |
| MY (1) | MY121105A (pl) |
| NO (1) | NO327285B1 (pl) |
| NZ (1) | NZ511010A (pl) |
| PE (1) | PE20001110A1 (pl) |
| PL (1) | PL198850B1 (pl) |
| PT (1) | PT1121116E (pl) |
| RU (1) | RU2259826C2 (pl) |
| SK (2) | SK286596B6 (pl) |
| TR (1) | TR200101088T2 (pl) |
| TW (1) | TW577738B (pl) |
| WO (1) | WO2000021525A2 (pl) |
| ZA (1) | ZA200103001B (pl) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6569461B1 (en) | 1999-03-08 | 2003-05-27 | Merck & Co., Inc. | Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors |
| US6242003B1 (en) * | 2000-04-13 | 2001-06-05 | Novartis Ag | Organic compounds |
| AU2000250960A1 (en) | 2000-06-09 | 2001-12-17 | Lek Pharmaceuticals D.D. | Stable pharmaceutical product and formulation |
| SI1345595T1 (sl) * | 2000-09-29 | 2007-08-31 | Solvay Pharm Bv | Farmacevtska oblika s podaljĺ anim sproĺ äśanjem, ki je neodvisna od ionske jakosti |
| US20060127474A1 (en) | 2001-04-11 | 2006-06-15 | Oskar Kalb | Pharmaceutical compositions comprising fluvastatin |
| US20060039974A1 (en) * | 2002-09-11 | 2006-02-23 | Takeda Pharmaceutical Company Limited | Sustained release preparation |
| EP1615619A2 (en) | 2003-04-23 | 2006-01-18 | Ferring B.V. | Sachet for a pharmaceutical composition |
| US8987322B2 (en) | 2003-11-04 | 2015-03-24 | Circ Pharma Research And Development Limited | Pharmaceutical formulations for carrier-mediated transport statins and uses thereof |
| DE102004062475A1 (de) * | 2004-12-24 | 2006-07-06 | Bayer Healthcare Ag | Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung |
| KR100582347B1 (ko) * | 2004-12-30 | 2006-05-22 | 한미약품 주식회사 | 3-하이드록시-3-메틸글루타릴 조효소 ａ 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법 |
| WO2007016757A1 (en) * | 2005-08-05 | 2007-02-15 | Orbus Pharma Inc. | Stabilized extended release pharmeceutical compositions comprising an hmg-coa reductase inhibitor |
| BRPI0708191A2 (pt) * | 2006-02-24 | 2012-05-29 | Teva Pharma | " composições farmacêuticas de fluvastatina sódica " |
| RU2356532C2 (ru) * | 2007-06-01 | 2009-05-27 | Открытое Акционерное Общество "Отечественные Лекарства" | Фармацевтическая композиция проксодолола с контролируемым высвобождением |
| CN102805739B (zh) * | 2012-04-10 | 2013-08-14 | 宋芸 | 氟伐他汀钠缓释包衣滴丸及其制备方法 |
| MX2015008757A (es) * | 2013-01-09 | 2016-02-05 | Edgemont Pharmaceuticals Llc | Formulaciones de lorazepam de liberacion controlada. |
| CN106344535B (zh) * | 2016-08-29 | 2019-09-20 | 济南康和医药科技有限公司 | 一种氟伐他汀钠微孔渗透泵控释片及其制备方法 |
| JP2021505595A (ja) | 2017-12-05 | 2021-02-18 | サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | 結晶形およびその製造方法 |
| MX2020005518A (es) | 2017-12-05 | 2020-11-06 | Sunovion Pharmaceuticals Inc | Mezclas no racemicas y usos de las mismas. |
| AU2019350699B2 (en) | 2018-09-25 | 2024-05-23 | Ponce De Leon Health Designated Activity Company | Process of making calcium alpha-ketoglutarate |
| JP2022535893A (ja) | 2019-06-04 | 2022-08-10 | サノビオン ファーマシューティカルズ インク | 放出調節製剤およびその使用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4915954A (en) * | 1987-09-03 | 1990-04-10 | Alza Corporation | Dosage form for delivering a drug at two different rates |
| EP0465096A1 (en) * | 1990-06-26 | 1992-01-08 | Merck & Co. Inc. | Plasma cholesterol level lowering composition |
| GB9523752D0 (en) * | 1995-11-21 | 1996-01-24 | Pfizer Ltd | Pharmaceutical formulations |
| PT814782E (pt) * | 1995-12-22 | 2003-04-30 | Nissan Chemical Ind Ltd | Composicao farmaceutica estabilizada com um agente basico |
| SE9603667D0 (sv) * | 1996-10-08 | 1996-10-08 | Astra Ab | Pharmaceutical compositions |
-
1999
- 1999-10-05 CO CO99062951A patent/CO5140079A1/es unknown
- 1999-10-12 AU AU60909/99A patent/AU765475B2/en not_active Expired
- 1999-10-12 AT AT99947489T patent/ATE382345T1/de active
- 1999-10-12 KR KR10-2001-7004708A patent/KR100517090B1/ko active IP Right Grant
- 1999-10-12 PT PT99947489T patent/PT1121116E/pt unknown
- 1999-10-12 ES ES99947489T patent/ES2297936T3/es not_active Expired - Lifetime
- 1999-10-12 CN CNB998120812A patent/CN1196481C/zh not_active Expired - Lifetime
- 1999-10-12 IL IL14237599A patent/IL142375A0/xx unknown
- 1999-10-12 NZ NZ511010A patent/NZ511010A/en not_active IP Right Cessation
- 1999-10-12 BR BR9911648-0A patent/BR9911648A/pt not_active Application Discontinuation
- 1999-10-12 HU HU0104268A patent/HUP0104268A3/hu not_active Application Discontinuation
- 1999-10-12 DE DE69937891T patent/DE69937891T2/de not_active Expired - Lifetime
- 1999-10-12 ID IDW20010807A patent/ID29350A/id unknown
- 1999-10-12 JP JP2000575501A patent/JP2002527388A/ja active Pending
- 1999-10-12 TR TR2001/01088T patent/TR200101088T2/xx unknown
- 1999-10-12 PL PL348109A patent/PL198850B1/pl unknown
- 1999-10-12 SK SK5054-2008A patent/SK286596B6/sk not_active IP Right Cessation
- 1999-10-12 RU RU2001111882/15A patent/RU2259826C2/ru active
- 1999-10-12 PE PE1999001027A patent/PE20001110A1/es not_active IP Right Cessation
- 1999-10-12 DK DK99947489T patent/DK1121116T3/da active
- 1999-10-12 WO PCT/EP1999/007627 patent/WO2000021525A2/en active Application Filing
- 1999-10-12 CA CA002346868A patent/CA2346868C/en not_active Expired - Lifetime
- 1999-10-12 EP EP99947489A patent/EP1121116B1/en not_active Revoked
- 1999-10-12 AR ARP990105146A patent/AR020780A1/es not_active Application Discontinuation
- 1999-10-12 SK SK509-2001A patent/SK286595B6/sk not_active IP Right Cessation
- 1999-10-13 MY MYPI99004430A patent/MY121105A/en unknown
- 1999-10-14 TW TW088117692A patent/TW577738B/zh not_active IP Right Cessation
-
2001
- 2001-04-02 IL IL142375A patent/IL142375A/en not_active IP Right Cessation
- 2001-04-04 NO NO20011695A patent/NO327285B1/no not_active IP Right Cessation
- 2001-04-11 ZA ZA200103001A patent/ZA200103001B/en unknown
-
2002
- 2002-04-10 HK HK02102698.9A patent/HK1040920B/zh not_active IP Right Cessation
-
2006
- 2006-08-14 JP JP2006221194A patent/JP4938383B2/ja not_active Expired - Fee Related
-
2008
- 2008-02-04 CY CY20081100134T patent/CY1107874T1/el unknown
- 2008-11-11 AR ARP080104921A patent/AR069281A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO327285B1 (no) | Farmasoytisk sammensetning med langvarig frigivelse og anvendelse derav | |
| US5032406A (en) | Dual-action tablet | |
| JP5888549B2 (ja) | 医薬組成物 | |
| KR101406767B1 (ko) | 프라미펙솔 또는 약제학적으로 허용되는 이의 염을함유하는 연장 방출성 정제 제형, 이의 제조방법 및 이의용도 | |
| US5948437A (en) | Pharmaceutical compositions using thiazepine | |
| NO173317B (no) | Fremgangsmaate for fremstilling av et fast farmasoeytisk preparat med forsinket frigjoering | |
| RU2466717C2 (ru) | Фармацевтический твердый препарат, содержащий бензоазепины, и способ его получения | |
| NO331689B1 (no) | Oral farmasoytisk sammensetning omfattende rivastigmin, samt anvendelse av rivastigmin | |
| NO340960B1 (no) | Modifiserte frigivende tamsulosintabletter | |
| US20110257239A1 (en) | Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent | |
| US6333361B1 (en) | Pharmaceutical composition containing zafirlukast | |
| US20040127541A1 (en) | Bicifadine formulation | |
| WO2008124611A1 (en) | Pharmaceutical compositions comprising ramipril and indapamide | |
| EP1560568B1 (en) | Controlled release pharmaceutical compositions containing sodium alginate and sodium calcium alginate | |
| US20040228918A1 (en) | Granule modulating hydrogel system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |